CAR- T Cell Therapy Market Overview, Drivers and Impact of Coronavirus (COVID-19) Pandemic
- Get link
- Other Apps
CAR T-cell treatment with chimeric antigen receptors (CAR) is a method of obtaining immune cells known as T cells. CAR T-cell therapy is used to treat lymphomas, leukemias, and multiple myeloma, among other diseases. Many clinical trials for CAR T-cell treatments have been done around the world in order to expand the therapy options for cancer. In 2010, the National Cancer Institute's research team published the first study on CAR T-cell therapy, a new type of cancer treatment.
Global Car T Cell Therapy Market –
Impact of Coronavirus (COVID-19) Pandemic
As a result
of the COVID–19 outbreak and a reduction of global research effort, many firms
around the world have seen their operations and financial performance
deteriorate. The closing of academic and scientific institutes, as well as
testing facilities, has had a significant detrimental impact. As a result, the CAR-T cell therapy market trials have been pushed back.
CAR-T Cell Therapy Market |
COVID-19 is
a serious hazard to the health of susceptible patients, such as those who are
immunocompromised. Due to their severely immunocompromised state, induced by
past lymphodepleting immunochemotherapy and CAR-T-cell therapy-related side
effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias, CAR T-cell
therapy recipients are at a significant risk of poor COVID-19.
Car T Cell Therapy Market Drivers
Because of
the rising prevalence of cancer patients around the world, the CAR T treatment
industry is predicted to rise. Because of the amazing responses it has elicited
in patients, this treatment has piqued the interest of researchers and the
general public. In 2017, the Food and Drug Administration (FDA) approved two
CAR T therapies, one for children with ALL and the other for adults with
advanced lymphomas.
The use of
chimeric antigen receptors for cancer treatment has seen steady increase in the
biotechnology and life science industries. Patient assistance programmes
(PAPs), increased government cancer awareness activities, rising cancer
prevalence worldwide, and strong R&D initiatives from leading businesses
are all propelling the CAR-T
cell therapy market forward. Producers have begun investing in the
manufacturing of cell-based therapy in response to the increased demand for it.
- Get link
- Other Apps
Comments
Post a Comment